Alnylam On Its Back Foot Heading Into A Major Event

Alnylam (ALNY) needs some good news and its upcoming Phase III APOLLO read-out on patisiran really needs to hit the mark with respect to efficacy and safety. With a $7 billion market cap, a lot is still expected of this company even though it has had more than a few setbacks in the past year. Programs in hemophilia, porphyria, and cholesterol still have worthwhile potential, but yet another major setback would seriously diminish management credibility and investor confidence in what is still an unproven platform.

Click here for more:
Alnylam On Its Back Foot Heading Into A Major Event